Insights from 2023 ESMO Annual Meeting
P

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-756 & BEGONIA"

By Insights from 2023 ESMO Annual Meeting FEATURING Paolo Tarantino
November 3, 2023
1 Comment
Login to view comments. Click here to Login

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Featured Video

18:08
Novartis Oncology

Expert Discussion: What Is a Key Driver of HR+/HER2- mBC?

Feat. D. Juric

Related Content

AUTOPLAY
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
17:39
Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
04:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney
18:08
Novartis Oncology

Expert Discussion: What Is a Key Driver of HR+/HER2- mBC?

Feat. D. Juric
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
23:58
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
50:59
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"

Feat. S. Tolaney, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi
53:42
PleXus Communications

Managing Woman's Health in Menopause: Evolving Approaches for t…

Feat. J. Simon, T. Iyer, A. Fiffick, M. Minkin
18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi
18:49
Yale School of Medicine

Menopause and Hot Flashes: What Medications are Available?

Feat. M. Minkin
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Optimal Duration of Endocrine Therapy for Breast Cancer

Feat. V. Kaklamani
03:05
ecancer

ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…

Feat. D. Slamon
05:45
SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang